Ivosimab and chemo before surgery for liver-only CRC spread
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called ivosimab combined with chemotherapy before surgery for people with colorectal cancer that has spread only to the liver. The goal is to shrink the liver tumors so they can be completely removed and improve the chance of cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread only to your liver and your tumor is mismatch repair proficient (pMMR) or microsatellite stable (MSS).
- You have not received prior treatment for the liver metastases, and if you had treatment more than a year ago for colorectal cancer elsewhere, that may be okay.
- Your liver metastases can be completely removed by surgery and the remaining liver will be healthy enough afterward.
- You are at least 18 and no older than 75, with good overall health (ECOG 0-1), and your organs (kidney, liver, bone marrow) are working well.
- You have not been treated with immunotherapy before (like anti-PD-1, anti-PD-L1, or anti-CTLA4).
- You do not have any active autoimmune disease, serious heart condition, uncontrolled infection (like hepatitis B or C), or a history of another cancer in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people whose colorectal cancer has spread to other parts of the body but not to the liver. The goal is to see if this combination works better than current treatments for this specific type of cancer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted therapy (bevacizumab) to shrink liver metastases from colorectal cancer that cannot be surgically removed right now. The goal is to make the tumors small enough for surgery.
This trial tests a combination of three chemotherapy drugs (liposomal irinotecan, oxaliplatin, and capecitabine) given directly into the liver blood vessel after surgery to remove colorectal cancer that has spread to the liver. The goal is to reduce the chance of cancer coming back.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
Hear when a new Colorectal Cancer With Liver Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.